These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17146155)

  • 1. Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
    Senba H; Kawano M; Kawakami M
    J Atheroscler Thromb; 2006 Oct; 13(5):263-4. PubMed ID: 17146155
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.
    Ebcioglu Z; Morgan J; Carey C; Capuzzi D
    Ann Intern Med; 2003 Nov; 139(9):W80. PubMed ID: 14597479
    [No Abstract]   [Full Text] [Related]  

  • 3. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Crook MA; Lynas J; Wray R
    J Clin Pathol; 2000 Oct; 53(10):796-7. PubMed ID: 11064678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate.
    Olukoga AO
    J Clin Pathol; 2002 Sep; 55(9):718. PubMed ID: 12195008
    [No Abstract]   [Full Text] [Related]  

  • 5. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
    Smud R; Sermukslis B
    Curr Med Res Opin; 1987; 10(9):612-24. PubMed ID: 3436157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting.
    Bhargava A; Gleason S; Vaughan AG; Johnson JF; Yarlagadda KV
    Int J Clin Pract; 2013 Nov; 67(11):1151-8. PubMed ID: 24165429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe HDL-c reduction during rosiglitazone therapy in an obese woman with type 2 diabetes.
    Almeida RL; Fedrizzi P; Fedrizzi D; Almeida TS
    Arq Bras Endocrinol Metabol; 2010 Oct; 54(7):663-7. PubMed ID: 21085773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
    Jun JK; Gong WC; Mathur R
    Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
    [No Abstract]   [Full Text] [Related]  

  • 9. Paradoxical high-density lipoprotein reduction induced by fibrate therapy.
    Oleesky DA; Mir MA
    Ann Clin Biochem; 1997 Sep; 34 ( Pt 5)():573-4. PubMed ID: 9293321
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
    Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
    Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.
    Leonard CE; Han X; Bilker WB; Flory JH; Brensinger CM; Flockhart DA; Gagne JJ; Cardillo S; Hennessy S
    Diabetes Res Clin Pract; 2016 May; 115():60-7. PubMed ID: 27242124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
    Normén L; Frohlich J; Montaner J; Harris M; Elliott T; Bondy G
    Diabetes Care; 2004 Sep; 27(9):2241-2. PubMed ID: 15333491
    [No Abstract]   [Full Text] [Related]  

  • 13. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin potentiation with bezafibrate.
    Beringer TR
    Postgrad Med J; 1997 Oct; 73(864):657-8. PubMed ID: 9497982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate: reply by the authors.
    Crook M; Lynas J; Wray R
    J Clin Pathol; 2002 Dec; 55(12):976. PubMed ID: 12461074
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukopenia and thrombocytopenia caused by thiazolidinediones.
    Digman C; Klein AK; Pittas AG
    Ann Intern Med; 2005 Sep; 143(6):465-6. PubMed ID: 16172449
    [No Abstract]   [Full Text] [Related]  

  • 19. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rhabdomyolysis due to bezafibrate in CAPD patients. A role for dihydropyridine drugs?
    Weissgarten J; Zaidenstein R; Fishman S; Dishi V; Michovitz-Koren M; Averbukh Z; Golik A
    Perit Dial Int; 1999; 19(2):180-2. PubMed ID: 10357195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.